/GBT

GBT Stock - Global Blood Therapeutics, Inc.

Q: What is the analyst price target for GBT?

Analyst price target information is not currently available for GBT.

Q: What is GBT's market cap?

Market capitalization information is not currently available for GBT.

Healthcare|Biotechnology|NASDAQ

$68.49+0.01%

+$0.01 (+0.01%) • Oct 4

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-11.8%upside

Target: $60.41

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GBT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.46

52W High$73.02

52W Low$21.65

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$194.75M	$123.80M	$2.11M	N/A	N/A
Gross Profit	$191.43M	$121.82M	$2.06M	N/A	N/A
Gross Margin	98.3%	98.4%	97.7%	N/A	N/A
Operating Income	$-287,147,000	$-243,172,000	$-281,283,000	$-182,742,000	$-119,245,000
Net Income	$-303,091,000	$-247,553,000	$-266,766,000	$-174,193,000	$-117,024,000
Net Margin	-155.6%	-200.0%	-12654.9%	N/A	N/A
EPS	$-4.82	$-4.04	$-4.57	$-3.41	$-2.76

Company Overview

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

$72

Average Target

↑ 5.1% Upside

Now

$72

Low

$72

Average

$72

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 8th 2022	William Blair	Downgrade	Market Perform	-
August 8th 2022	Canaccord Genuity	Upgrade	Buy	$72← $40

Earnings History & Surprises

GBT

Beat Rate

42%

Last 19 quarters

Avg Surprise

-3.9%

EPS vs Estimate

Beats / Misses

8/11

Last 12 quarters

Latest EPS

$-1.26

Q3 2022

EPS Surprise History

Q4 20

-27.6%

$-0.97vs$-0.76

Q1 21

-6.4%

$-1.00vs$-0.94

Q2 21

-19.8%

$-1.21vs$-1.01

Q3 21

+5.9%

$-1.12vs$-1.19

Q4 21

-1.8%

$-1.13vs$-1.11

Q1 22

-20.4%

$-1.36vs$-1.13

Q2 22

+3.1%

$-1.26vs$-1.30

Q3 22

-6.8%

$-1.26vs$-1.18

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2022	Nov 2, 2022	$-1.06	—	—	—
Q3 2022	Aug 8, 2022	$-1.18	$-1.26	-6.8%	✗ MISS
Q2 2022	May 4, 2022	$-1.30	$-1.26	+3.1%	✓ BEAT
Q1 2022	Feb 23, 2022	$-1.13	$-1.36	-20.4%	✗ MISS
Q4 2021	Nov 4, 2021	$-1.11	$-1.13	-1.8%	✗ MISS
Q3 2021	Aug 3, 2021	$-1.19	$-1.12	+5.9%	✓ BEAT
Q2 2021	May 5, 2021	$-1.01	$-1.21	-19.8%	✗ MISS
Q1 2021	Feb 24, 2021	$-0.94	$-1.00	-6.4%	✗ MISS
Q4 2020	Nov 5, 2020	$-0.76	$-0.97	-27.6%	✗ MISS
Q3 2020	Aug 5, 2020	$-1.15	$-0.86	+25.2%	✓ BEAT
Q2 2020	May 6, 2020	$-1.51	$-1.20	+20.5%	✓ BEAT
Q1 2020	Feb 26, 2020	$-1.24	$-1.59	-28.2%	✗ MISS
Q4 2019	Nov 7, 2019	$-1.05	$-1.07	-1.9%	✗ MISS
Q3 2019	Aug 7, 2019	$-0.96	$-1.01	-5.2%	✗ MISS
Q2 2019	May 8, 2019	$-0.94	$-0.87	+7.4%	✓ BEAT
Q1 2019	Feb 27, 2019	$-0.89	$-0.93	-4.5%	✗ MISS
Q4 2018	Nov 6, 2018	$-0.86	$-0.83	+3.5%	✓ BEAT
Q3 2018	Aug 2, 2018	$-0.88	$-0.78	+11.4%	✓ BEAT
Q2 2018	May 7, 2018	$-0.91	$-0.87	+4.4%	✓ BEAT
Q1 2018	Feb 27, 2018	$-0.71	$-0.94	-32.4%	✗ MISS

Frequently Asked Questions about GBT

What is GBT's current stock price?

Global Blood Therapeutics, Inc. (GBT) is currently trading at $68.49 per share. The stock has moved +0.01% today.

What is the analyst price target for GBT?

The average analyst price target for GBT is $60.38, based on 1 analyst.

What sector is Global Blood Therapeutics, Inc. in?

Global Blood Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is GBT's market cap?

Global Blood Therapeutics, Inc. has a market capitalization of N/A, making it a small-cap company.

Does GBT pay dividends?

No, Global Blood Therapeutics, Inc. does not currently pay a dividend to shareholders.